Cargando…

Progress towards a glycoconjugate vaccine against Group A Streptococcus

The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising a rhamnose backbone and GlcNAc side chains, further decorated with glycerol phosphate on approximately 40% GlcNAc residues. Its c...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Keira, Dorfmueller, Helge C., Wren, Brendan W., Mawas, Fatme, Shaw, Helen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043865/
https://www.ncbi.nlm.nih.gov/pubmed/36977677
http://dx.doi.org/10.1038/s41541-023-00639-5
_version_ 1784913244967665664
author Burns, Keira
Dorfmueller, Helge C.
Wren, Brendan W.
Mawas, Fatme
Shaw, Helen A.
author_facet Burns, Keira
Dorfmueller, Helge C.
Wren, Brendan W.
Mawas, Fatme
Shaw, Helen A.
author_sort Burns, Keira
collection PubMed
description The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising a rhamnose backbone and GlcNAc side chains, further decorated with glycerol phosphate on approximately 40% GlcNAc residues. Its conservation, surface exposure and antigenicity have made it an interesting focus on Strep A vaccine design. Glycoconjugates containing this conserved carbohydrate should be a key approach towards the successful mission to build a universal Strep A vaccine candidate. In this review, a brief introduction to GAC, the main carbohydrate component of Strep A bacteria, and a variety of published carrier proteins and conjugation technologies are discussed. Components and technologies should be chosen carefully for building affordable Strep A vaccine candidates, particularly for low- and middle-income countries (LMICs). Towards this, novel technologies are discussed, such as the prospective use of bioconjugation with PglB for rhamnose polymer conjugation and generalised modules for membrane antigens (GMMA), particularly as low-cost solutions to vaccine production. Rational design of “double-hit” conjugates encompassing species specific glycan and protein components would be beneficial and production of a conserved vaccine to target Strep A colonisation without invoking an autoimmune response would be ideal.
format Online
Article
Text
id pubmed-10043865
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100438652023-03-28 Progress towards a glycoconjugate vaccine against Group A Streptococcus Burns, Keira Dorfmueller, Helge C. Wren, Brendan W. Mawas, Fatme Shaw, Helen A. NPJ Vaccines Review Article The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising a rhamnose backbone and GlcNAc side chains, further decorated with glycerol phosphate on approximately 40% GlcNAc residues. Its conservation, surface exposure and antigenicity have made it an interesting focus on Strep A vaccine design. Glycoconjugates containing this conserved carbohydrate should be a key approach towards the successful mission to build a universal Strep A vaccine candidate. In this review, a brief introduction to GAC, the main carbohydrate component of Strep A bacteria, and a variety of published carrier proteins and conjugation technologies are discussed. Components and technologies should be chosen carefully for building affordable Strep A vaccine candidates, particularly for low- and middle-income countries (LMICs). Towards this, novel technologies are discussed, such as the prospective use of bioconjugation with PglB for rhamnose polymer conjugation and generalised modules for membrane antigens (GMMA), particularly as low-cost solutions to vaccine production. Rational design of “double-hit” conjugates encompassing species specific glycan and protein components would be beneficial and production of a conserved vaccine to target Strep A colonisation without invoking an autoimmune response would be ideal. Nature Publishing Group UK 2023-03-28 /pmc/articles/PMC10043865/ /pubmed/36977677 http://dx.doi.org/10.1038/s41541-023-00639-5 Text en © Crown 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Burns, Keira
Dorfmueller, Helge C.
Wren, Brendan W.
Mawas, Fatme
Shaw, Helen A.
Progress towards a glycoconjugate vaccine against Group A Streptococcus
title Progress towards a glycoconjugate vaccine against Group A Streptococcus
title_full Progress towards a glycoconjugate vaccine against Group A Streptococcus
title_fullStr Progress towards a glycoconjugate vaccine against Group A Streptococcus
title_full_unstemmed Progress towards a glycoconjugate vaccine against Group A Streptococcus
title_short Progress towards a glycoconjugate vaccine against Group A Streptococcus
title_sort progress towards a glycoconjugate vaccine against group a streptococcus
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043865/
https://www.ncbi.nlm.nih.gov/pubmed/36977677
http://dx.doi.org/10.1038/s41541-023-00639-5
work_keys_str_mv AT burnskeira progresstowardsaglycoconjugatevaccineagainstgroupastreptococcus
AT dorfmuellerhelgec progresstowardsaglycoconjugatevaccineagainstgroupastreptococcus
AT wrenbrendanw progresstowardsaglycoconjugatevaccineagainstgroupastreptococcus
AT mawasfatme progresstowardsaglycoconjugatevaccineagainstgroupastreptococcus
AT shawhelena progresstowardsaglycoconjugatevaccineagainstgroupastreptococcus